Table.

Comparison of pharmacological properties of neuraminidase inhibitors

	Zanamivir	Oseltamivir
Age approved for prophylaxis6, 7	>5 years	>13 years
Age approved for treatment6, 7	>5 years	>1 year
Renal impairment6, 7	No dose adjustment required	Adjustment if creatinine clearance 10–30 mL/min
Hepatic impairment6, 7	No dose adjustment required	Safety not established
Reduction of influenza symptoms8, 9	By median of 1·5 day	By median of 1·3 day
Adverse reactions6, 7	Allergy—very rare	Nausea 7·0–10·7%
	Bronchospasm and	Vomiting 2·1–8·0%
	dyspnoea—very rare	Diarrhoea 3·2–5·5%
	Rash and urticaria—very rare	Bronchitis 0·7–3·7%
		Headache 1·6–20·1%
		Fatigue 0·8–7·9%
Frequency of drug resistance after treatment10, 11	None reported	1·3 and 8·6–18·0% in adults and children, respectively